

# Measure Information Form (MIF): Community-Onset Sepsis – 30-Day Mortality

## Patient Safety Measure Development and Maintenance

---

Patrick Romano, MD<sup>1</sup>, Christian Sandrock, MD<sup>1</sup>, Garth Utter<sup>1</sup>, MD, Meghan Weyrich<sup>1</sup>, Mia Nievera, MSN, RN<sup>3</sup>, Christina Superina<sup>2</sup>, and Courtney Colahan<sup>2</sup>

<sup>1</sup>*University of California, Davis*

<sup>2</sup>*Kennell & Associates*

<sup>3</sup>*American Institutes for Research*

May 2022



Notice of Trademark: “American Institutes for Research” and “AIR” are registered trademarks. All other brand, product, or company names are trademarks or registered trademarks of their respective owners.

Copyright © 2021 American Institutes for Research®. All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, website display, or other electronic or mechanical methods, without the prior written permission of the American Institutes for Research. For permission requests, please use the Contact Us form on [AIR.ORG](https://www.air.org).

**SUBMITTED TO**

Centers for Medicare & Medicaid Services (CMS)  
Center for Clinical Standards and Quality (CCSQ)

**ATTENTION**

Donta Henson  
Centers for Medicare & Medicaid Services  
7500 Security Boulevard  
Baltimore, MD 21244-1850

**SUBMITTED BY**

American Institutes for Research  
1400 Crystal Drive, 10<sup>th</sup> Floor  
Arlington, VA 22202-3289  
(202)403-5000  
www.air.org

**PROJECT**

Patient Safety Measure Development and Maintenance  
Contract Number: 75FCMC18D0027

**TASK & DELIVERABLE**

Chapter 3 Information Gathering  
Deliverable 3-3 Measure Information Form

**AUTHORS**

Patrick Romano, University of California-Davis  
Christian Sandrock, University of California-Davis  
Garth Utter, University of California-Davis  
Meghan Weyrich, University of California-Davis  
Mia Nievera, AIR  
Christina Superina, Kennell and Associates  
Courtney Colahan, Kennell and Associates

## TABLE OF CONTENTS

Overview .....	4
1. Measure Name.....	4
2. Descriptive Information .....	4
2.1 Measure Type .....	4
2.2 Brief Description of Measure .....	4
2.3 If Paired or Grouped .....	4
3. Measure Specifications .....	5
3.1 Measure-specific Web Page.....	5
3.2 HQMF Specifications .....	5
3.3 Data Dictionary, Code, Table, or Value Sets .....	5
3.4 Instrument-Based Measure .....	6
3.5 Endorsement Maintenance .....	6
3.6 Numerator Statement.....	6
3.7 Numerator Details.....	6
3.8 Denominator Statement .....	6
3.9 Denominator Details .....	6
3.10 Denominator Exclusions .....	8
3.11 Denominator Exclusion Details .....	8
3.12 Stratification Details and Variables.....	8
3.13 Risk Adjustment Type .....	8
3.14 Type of score.....	8
3.15 Interpretation of Score .....	8
3.16 Calculation Algorithm and Measure Logic.....	9
3.17 Sampling.....	10
3.18 Survey/Patient-Reported Data.....	10
3.19 Data Source.....	10
3.20 Data Source or Collection Instrument .....	10
3.21 Data Source or Collection Instrument Reference .....	10
3.22 Level of Analysis .....	10
3.23 Care Setting.....	11
3.24 Composite Performance Measure .....	11

---

# Overview

**PROJECT TITLE:** Patient Safety Measure Development and Maintenance

**DATE:** Information included is current as of May 13, 2022.

**PROJECT OVERVIEW:** The Centers for Medicare & Medicaid Services (CMS) has contracted with AIR to develop, maintain, reevaluate, and implement patient safety measures for CMS' hospital-level quality reporting programs. The contract name is Patient Safety Measure Development and Maintenance. The contract number is 75FCMC18D0027 (Task Order: 75FCMC19F0001)

---

## 1. Measure Name

Community-Onset Sepsis – 30-Day Mortality

---

## 2. Descriptive Information

### 2.1 MEASURE TYPE

Outcome

### 2.2 BRIEF DESCRIPTION OF MEASURE

This hybrid electronic clinical quality measure (eCQM), with risk adjustment, assesses the proportion of inpatient hospitalizations for adult patients admitted with community-acquired sepsis who die within 30 days of presentation.

The detailed specifications for this measure are still in development and this measure has not gone through the testing process.

### 2.3 IF PAIRED OR GROUPED

Not Applicable.

---

## 3. Measure Specifications

### 3.1 MEASURE-SPECIFIC WEB PAGE

Not Applicable

### 3.2 HQMF SPECIFICATIONS

The detailed specifications for this measure are still in development and have not gone through the testing process.

### 3.3 DATA DICTIONARY, CODE, TABLE, OR VALUE SETS

Codes are still in development undergoing review.

Value Set Name	Hyperlink to the Value Set Authority Center
Anticoagulants for All Indications	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.22">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.22</a>
aPTT Tests	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.109">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.109</a>
Bilirubin Mass Per Volume	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.108">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.108</a>
Body temperature	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1045.152">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1045.152</a>
COVID 19	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.140">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.140</a>
Creatinine Mass Per Volume	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.21">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.21</a>
Discharged Against Medical Advice	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.110">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.110</a>
Discharged Alive	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.111">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.111</a>
Do Not Resuscitate Status	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.129">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.129</a>
Heart Rate	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.100">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.100</a>
Hospice Care	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.112">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.112</a>
Immune Modulators	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.124">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.124</a>
Infection	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.98">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.98</a>
Influenza	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.116">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.116</a>
INR	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.117.1.7.1.213">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.117.1.7.1.213</a>
IV Antibiotics for Sepsis	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.17.4077.2.2059">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.17.4077.2.2059</a>
Mean Arterial Pressure	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.103">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.103</a>
Mechanical Ventilation	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.107">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.107</a>
Medicare payer	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1104.10">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1104.10</a>
Platelet Count	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.117.1.7.1.267">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.117.1.7.1.267</a>
Present on Admission or Clinically Undetermined	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1147.197">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1147.197</a>
Respiratory Rate	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.101">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.101</a>
Sepsis	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.99">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.99</a>
Systolic Blood Pressure	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.104">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.104</a>
Vasopressors	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.102">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1248.102</a>
White blood cells count lab test	<a href="https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1045.129">https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1045.129</a>

### **3.4 INSTRUMENT-BASED MEASURE**

Not Applicable.

### **3.5 ENDORSEMENT MAINTENANCE**

Not Applicable. This is a *de novo* measure.

### **3.6 NUMERATOR STATEMENT**

Discharges for patients meeting the denominator criteria who die within 30 days of presentation to the hospital with severe sepsis.

The detailed specifications for this measure are still in development and has not gone through the testing process.

### **3.7 NUMERATOR DETAILS**

This is a hybrid eCQM, and therefore uses electronic health record data together with data from Medicare claims and Medicare beneficiary eligibility files to calculate the measure score. The time period for data collection begins during an inpatient hospitalization, at hospital arrival (whether through emergency department, observation stay, or directly admitted as inpatient), and encompasses all deaths within 30 days recorded by Medicare.

Additional details of the specifications for this measure are still in development.

### **3.8 DENOMINATOR STATEMENT**

Inpatient hospitalizations of Medicare beneficiaries between 18 and 115 years of age at the start of the encounter meeting the definition for severe sepsis.

### **3.9 DENOMINATOR DETAILS**

This measure includes all Medicare beneficiaries between 18 and 115 years of age at the time of admission. Measurement period is one year. The measure is at the hospital admission level; only one numerator event is counted per encounter.

Severe sepsis is defined as a combination of clinical findings, suspected infection, and organ dysfunction, as follows:

- Clinical findings, based on Systemic Inflammatory Response Syndrome (SIRS) criteria ( $\geq 2$  of the following criteria within 6 hours of presentation):
  - Temperature  $>38^{\circ}\text{C}$  or  $<36^{\circ}\text{C}$
  - HR  $>90/\text{min}$
  - RR  $>20/\text{min}$
  - WBC  $>12,000$  or  $<4,000$  cells/ $\text{mm}^3$
- Suspected infection (either of the following criteria):
  - ICD-10-CM diagnosis of infection (of suspected bacterial origin) or sepsis present on admission (POA)
  - Administration of antibiotics within 30 hours of presentation and continuation for  $\geq 3$  days or until discharge
- Presence of organ dysfunction ( $\geq 1$  of the following criteria within 6 hours of presentation, in the absence of an alternative explanation):
  - Administration of vasopressors
  - Mean arterial pressure (MAP)  $<65$  mmHg or Systolic Blood Pressure (SBP)  $<90$  mmHg
  - Initiation of mechanical ventilation
  - Creatinine  $>2.0$  mg/dL (and at least 0.5 greater than, or 2x, baseline value)
  - Total bilirubin  $>2.0$  mg/dL
  - Platelet count  $<100,000/\text{mm}^3$
  - INR  $>1.5$  or aPTT  $>60$  sec

The detailed specifications for this measure are still in development and has not gone through the testing process.

### **3.10 DENOMINATOR EXCLUSIONS**

Exclude inpatient hospitalizations for patients:

- Who lack continuous Medicare fee-for-service (FFS) Part A and B enrollment. Continuous enrollment is a duration of at least 30 days before through 30 days after the encounter start date
- Discharged against medical advice
- Discharged alive within 6 hours of presentation
- Who had a prior enrollment in hospice
- Who had a prior inpatient episode of sepsis within a 30-day window (not transferred)
- Who had a hospitalization following transfer from another facility's ED or inpatient care
- Who had an influenza or COVID-19 infection present on admission

### **3.11 DENOMINATOR EXCLUSION DETAILS**

TBD. The detailed specifications for this measure are still in development.

### **3.12 STRATIFICATION DETAILS AND VARIABLES**

Not Applicable.

### **3.13 RISK ADJUSTMENT TYPE**

Statistical risk model

### **3.14 TYPE OF SCORE**

Rate/proportion

### **3.15 INTERPRETATION OF SCORE**

A lower score is indicative of better quality.



### 3.16 CALCULATION ALGORITHM AND MEASURE LOGIC

To calculate the hospital-level measure result, divide the total numerator events by the total number of qualifying encounters (denominator).

Qualifying encounters (denominator) include inpatient hospitalizations of Medicare beneficiaries between 18 and 115 years of age at the start of the encounter who meet the definition for severe sepsis.

Severe sepsis is defined as a combination of clinical findings, suspected infection, and organ dysfunction, as follows:

Clinical findings, based on Systemic Inflammatory Response Syndrome (SIRS) criteria ( $\geq 2$  of the following criteria within 6 hours of presentation):

- Temperature  $>38^{\circ}\text{C}$  or  $<36^{\circ}\text{C}$
- HR  $>90/\text{min}$
- RR  $>20/\text{min}$
- WBC  $>12,000$  or  $<4,000$  cells/ $\text{mm}^3$

Suspected infection (any one of the following criteria):

- Diagnosis of infection (of suspected bacterial origin) present on admission (POA)
- Diagnosis of sepsis present on admission (POA)
- Administration of antibiotics within 30 hours of presentation and continuation for  $\geq 3$  days or until discharge

Presence of organ dysfunction ( $\geq 1$  of the following criteria within 6 hours of presentation, in the absence of an alternative explanation):

- Administration of vasopressors
- Mean arterial pressure (MAP)  $<65$  mmHg or Systolic Blood Pressure (SBP)  $<90$  mmHg
- Initiation of mechanical ventilation
- Creatinine  $>2.0$  mg/dL (and at least 0.5 greater than, or 2x, baseline value)
- Total bilirubin  $>2.0$  mg/dL
- Platelet count  $<100,000/\text{mm}^3$
- INR  $>1.5$  or aPTT  $>60$  sec Start with those encounters that meet the denominator.

Remove all encounters for patients:

- Who lack of continuous Medicare fee-for-service (FFS) Part A and B enrollment. Continuous enrollment is a duration of at least 30 days before through 30 days after the encounter start date

- Discharged against medical advice
- Discharged alive within 6 hours of presentation
- Who had a prior enrollment in hospice
- Who had a prior inpatient episode of sepsis within a 30-day window (not transferred)
- Who had a hospitalization following transfer from another facility's ED or inpatient care
- Who had an influenza or COVID-19 infection present on admission

To create the numerator, count those discharges for patients who die within 30 days of presentation to the hospital with severe sepsis.

### **3.17 SAMPLING**

Not Applicable

### **3.18 SURVEY/PATIENT-REPORTED DATA**

Not Applicable

### **3.19 DATA SOURCE**

Electronic clinical health record data and Medicare claims data

### **3.20 DATA SOURCE OR COLLECTION INSTRUMENT**

Hospitals collect EHR data using certified electronic health record technology (CEHRT). The MAT output includes the human readable and XML artifacts of the clinical quality language (CQL) for the measure. No additional tools are used for data collection for eQMs. Claims data and data from the Medicare beneficiary eligibility files are also used.

### **3.21 DATA SOURCE OR COLLECTION INSTRUMENT REFERENCE**

No data collection instrument is used.

### **3.22 LEVEL OF ANALYSIS**

Facility

### **3.23 CARE SETTING**

Inpatient/Hospital

### **3.24 COMPOSITE PERFORMANCE MEASURE**

Not Applicable